These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 28239465)

  • 1. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
    Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
    Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
    Steinerová K; Jindra P; Lysák D; Karas M
    Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.
    Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H
    Swiss Med Wkly; 2019 Nov; 149():w20150. PubMed ID: 31707719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Beköz H; Karadurmuş N; Paydaş S; Türker A; Toptaş T; Fıratlı Tuğlular T; Sönmez M; Gülbaş Z; Tekgündüz E; Kaya AH; Özbalak M; Taştemir N; Kaynar L; Yıldırım R; Karadoğan I; Arat M; Pepedil Tanrıkulu F; Özkocaman V; Abalı H; Turgut M; Kurt Yüksel M; Özcan M; Doğu MH; Kabukçu Hacıoğlu S; Barışta I; Demirkaya M; Köseoğlu FD; Toprak SK; Yılmaz M; Demirkürek HC; Demirkol O; Ferhanoğlu B
    Ann Oncol; 2017 Oct; 28(10):2496-2502. PubMed ID: 28961828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
    Merryman RW; Kim HT; Zinzani PL; Carlo-Stella C; Ansell SM; Perales MA; Avigdor A; Halwani AS; Houot R; Marchand T; Dhedin N; Lescaut W; Thiebaut-Bertrand A; François S; Stamatoullas-Bastard A; Rohrlich PS; Labussière Wallet H; Castagna L; Santoro A; Bachanova V; Bresler SC; Srivastava A; Kim H; Pesek E; Chammas M; Reynolds C; Ho VT; Antin JH; Ritz J; Soiffer RJ; Armand P
    Blood; 2017 Mar; 129(10):1380-1388. PubMed ID: 28073785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
    Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
    Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.
    Klobuch S; Weber D; Holler B; Herr W; Holler E; Wolff D
    Oncol Res Treat; 2017; 40(7-8):447-450. PubMed ID: 28683452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Yared JA; Hardy N; Singh Z; Hajj S; Badros AZ; Kocoglu M; Yanovich S; Sausville EA; Ujjani C; Ruehle K; Goecke C; Landau M; Rapoport AP
    Bone Marrow Transplant; 2016 Jun; 51(6):850-2. PubMed ID: 26828905
    [No Abstract]   [Full Text] [Related]  

  • 14. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
    Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation.
    Kobayashi T; Guo YM; Yamashita T; Nara M; Yoshioka T; Kameoka Y; Fukuda T; Takahashi N
    Int J Hematol; 2019 Mar; 109(3):356-360. PubMed ID: 30604316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab in classical Hodgkin's lymphoma.
    Maly J; Alinari L
    Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
    Ogasawara R; Hashimoto D; Sugita J; Yamawaki F; Naka T; Mitsuhashi T; Takahashi S; Miyashita N; Okada K; Onozawa M; Matsuno Y; Teshima T
    Int J Hematol; 2020 Mar; 111(3):475-479. PubMed ID: 31538325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
    Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
    Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Aslan A; Aras T; Özdemir E
    Leuk Lymphoma; 2017 Mar; 58(3):754-755. PubMed ID: 27687237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.